TY - JOUR AU - Takada, Mamoru AU - Higuchi, Toru AU - Tozuka, Katsunori AU - Takei, Hiroyuki AU - Haruta, Masayuki AU - Watanabe, Junko AU - Kasai, Fumio AU - Inoue, Kenichi AU - Kurosumi, Masafumi AU - Miyazaki, Masaru AU - Sato-Otsubo, Aiko AU - Ogawa, Seishi AU - Kaneko, Yasuhiko PY - 2013 DA - 2013/05/16 TI - Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy JO - BMC Cancer SP - 241 VL - 13 IS - 1 AB - Chemotherapy with trastuzumab is widely used for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer, but a significant number of patients with the tumor fail to respond, or relapse. The mechanisms of recurrence and biomarkers that indicate the response to the chemotherapy and outcome are not fully investigated. SN - 1471-2407 UR - https://doi.org/10.1186/1471-2407-13-241 DO - 10.1186/1471-2407-13-241 ID - Takada2013 ER -